HPR91 Public Sector Replacement of Privately Funded Pharmaceutical RD: Cost and Efficiency Considerations

Abstract

Authors

U Neumann D Proudman S Martin H Grabowski

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×